Nasri Baongoc, Inokuchi Mikito, Ishikawa Toshiaki, Uetake Hiroyuki, Takagi Yoko, Otsuki Sho, Kojima Kazuyuki, Kawano Tatsuyuki
Matsuzawa Hospital, Setagaya-ku, Tokyo, Japan.
Department of Surgical Oncology, Graduate School, Tokyo Medical and Dental University, Bunkyo-ku, Tokyo, Japan.
BMC Clin Pathol. 2017 Apr 27;17:8. doi: 10.1186/s12907-017-0047-y. eCollection 2017.
As the major subfamily of receptor tyrosine, erythropoietin-producing hepatocellular (Eph) receptor has been related to progression and prognosis in different types of tumors. However, the role and mechanism of EPHA3 in gastric cancer is still not well understood.
Specimen were collected from 202 patients who underwent gastric resection for gastric adenocarcinoma. The expression of EphA3 was studied using immunohistochemistry. We analyzed the clinicopathological factors and prognostic relevance of EphA3 expression in gastric cancer.
High expression of EphA3 was associated with male predominance ( = 0.031), differentiated histology ( < 0.001), depth of tumor ( = 0.002), lymph node metastasis ( = 0.001), distant metastasis ( = 0.021), liver metastasis ( = 0.024), advanced stage ( < 0.001), and high HER2 expression ( = 0.017). Relapse-free survival (RFS) was significantly worse in patients with high expression of EphA3 than in those with low expression of EphA3 ( = 0.014). Multivariate analysis for RFS showed that depth of tumor [hazard ratio (HR) 9.333, 95% confidence interval (CI) 2.183-39.911, = 0.003] and lymph node metastasis [hazard ratio (HR) 5.734, 95% confidence interval (CI) 2.349-13.997, < 0.001] were independent prognostic factors.
These findings suggest that high expression EphA3 may participate in metastasis and worse survival.
作为受体酪氨酸的主要亚家族，促红细胞生成素产生肝细胞（Eph）受体与不同类型肿瘤的进展和预后相关。然而，EPHA3在胃癌中的作用和机制仍未完全明确。
收集202例行胃腺癌胃切除术患者的标本。采用免疫组织化学方法研究EphA3的表达。我们分析了EphA3表达在胃癌中的临床病理因素及预后相关性。
EphA3高表达与男性占优势（P = 0.031）、组织学分化（P < 0.001）、肿瘤深度（P = 0.002）、淋巴结转移（P = 0.001）、远处转移（P = 0.021）、肝转移（P = 0.024）、晚期（P < 0.001）及HER2高表达（P = 0.017）相关。EphA3高表达患者的无复发生存期（RFS）显著差于EphA3低表达患者（P = 0.014）。RFS的多因素分析显示肿瘤深度[风险比（HR）9.333，95%置信区间（CI）2.183 - 39.911，P = 0.003]和淋巴结转移[风险比（HR）5.734，95%置信区间（CI）2.349 - 13.997，P < 0.001]是独立的预后因素。
这些发现表明EphA3高表达可能参与转移并导致较差的生存率。
